TrialClinical pharmacology in drug development2025

Safety, Tolerability, and Pharmacokinetics of the Long-Acting SARS-CoV-2-Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults.

Nanyang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.